Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of RC88 in platinum-resistant recurrent ovarian, fallopian tube, and primary peritoneal cancer
CTR20233195Phase 2Completed
- Sponsor
- RemeGen
- Start
- Oct 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of misitatug blivedotin in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by RemeGen. Started Oct 2023; status: completed.
02
Drugs
misitatug blivedotin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20233195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233195.